CY1119502T1 - Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak) - Google Patents

Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)

Info

Publication number
CY1119502T1
CY1119502T1 CY20171101116T CY171101116T CY1119502T1 CY 1119502 T1 CY1119502 T1 CY 1119502T1 CY 20171101116 T CY20171101116 T CY 20171101116T CY 171101116 T CY171101116 T CY 171101116T CY 1119502 T1 CY1119502 T1 CY 1119502T1
Authority
CY
Cyprus
Prior art keywords
janus
jak
pyrimidine
pyrrolos
producers
Prior art date
Application number
CY20171101116T
Other languages
English (en)
Inventor
Matthew Frank Brown
Ashley Edward Fenwick
Mark Edward Flanagan
Andrea GONZALES
Timothy Allan JOHNSON
Neelu Kaila
Mark J. Mitton-Fry
Joseph Walter Strohbach
Ruth E. Tenbrink
John David TRZUPEK
Rayomand Jal Unwalla
Michael L. Vazquez
Mihir D. PARIKH
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of CY1119502T1 publication Critical patent/CY1119502T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member

Abstract

Περιγράφονται εις το παρόν παράγωγα πυρρολο{2,3-d}πυριμιδίνης, η χρήση αυτών ως αναστολείς της Κινάσης Janus (Ιανός) (JAK), και φαρμακευτικές συνθέσεις περιέχοντας αυτά.
CY20171101116T 2013-02-22 2017-10-26 Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak) CY1119502T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361767947P 2013-02-22 2013-02-22
PCT/IB2014/058889 WO2014128591A1 (en) 2013-02-22 2014-02-11 Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)

Publications (1)

Publication Number Publication Date
CY1119502T1 true CY1119502T1 (el) 2018-03-07

Family

ID=50151346

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171101116T CY1119502T1 (el) 2013-02-22 2017-10-26 Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)
CY20191100127T CY1121468T1 (el) 2013-02-22 2019-01-30 Συνδυασμος παραγωγων πυρρολο[2,3-d]πυριμιδινης με εναν ή περισσοτερους επιπροσθετους παραγοντες ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20191100127T CY1121468T1 (el) 2013-02-22 2019-01-30 Συνδυασμος παραγωγων πυρρολο[2,3-d]πυριμιδινης με εναν ή περισσοτερους επιπροσθετους παραγοντες ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)

Country Status (47)

Country Link
US (3) US9035074B2 (el)
EP (2) EP2958921B1 (el)
JP (2) JP6145179B2 (el)
KR (1) KR101787858B1 (el)
CN (2) CN107089985B (el)
AP (1) AP2015008664A0 (el)
AR (1) AR094857A1 (el)
AU (1) AU2014220357B2 (el)
BR (1) BR112015019634B1 (el)
CA (1) CA2900703C (el)
CL (1) CL2015002303A1 (el)
CR (1) CR20150395A (el)
CU (1) CU24275B1 (el)
CY (2) CY1119502T1 (el)
DK (2) DK2958921T3 (el)
DO (1) DOP2015000206A (el)
EA (1) EA027879B1 (el)
ES (2) ES2647525T3 (el)
FR (1) FR22C1006I2 (el)
GE (1) GEP201606600B (el)
HK (1) HK1213881A1 (el)
HR (2) HRP20171599T2 (el)
HU (3) HUE037192T2 (el)
IL (1) IL240132B (el)
LT (3) LT3290421T (el)
MA (1) MA38347A1 (el)
MD (1) MD4735C1 (el)
ME (2) ME03301B (el)
MX (1) MX2015010928A (el)
MY (1) MY177476A (el)
NL (1) NL301155I2 (el)
NO (1) NO3052752T3 (el)
NZ (1) NZ710411A (el)
PE (1) PE20151764A1 (el)
PH (1) PH12015501779B1 (el)
PL (2) PL3290421T3 (el)
PT (2) PT2958921T (el)
RS (2) RS58245B1 (el)
SG (1) SG11201505816UA (el)
SI (2) SI3290421T1 (el)
TN (1) TN2015000355A1 (el)
TR (1) TR201902525T4 (el)
TW (1) TWI507408B (el)
UA (1) UA111804C2 (el)
UY (1) UY35337A (el)
WO (1) WO2014128591A1 (el)
ZA (1) ZA201505454B (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103153053B (zh) 2010-08-18 2015-02-18 萨穆梅德有限公司 作为联蛋白信号通路激活剂的二酮与羟基酮
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
ME03296B (me) 2013-02-22 2019-07-20 Samumed Llc Gama-diketoni kao aktivatori wnt/beta-kateninakog signalnog puta
EP2958921B1 (en) 2013-02-22 2017-09-20 Pfizer Inc Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus kinases (jak)
WO2016024185A1 (en) * 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
AU2015305373B2 (en) 2014-08-20 2020-12-10 Samumed, Llc Gamma-diketones for treatment and prevention of aging skin and wrinkles
DK3305788T3 (da) * 2015-05-29 2020-09-28 Wuxi Fortune Pharmaceutical Co Ltd Janus-kinase-hæmmer
CN106831779B (zh) * 2015-11-28 2019-07-19 南昌弘益药业有限公司 一类jak激酶抑制剂的新化合物
US10973913B2 (en) 2016-02-16 2021-04-13 Washington University JAK inhibitors and uses thereof
EP3565520A4 (en) 2017-01-06 2020-08-19 Palvella Therapeutics, Inc. Anhydrous compositions of MTOR inhibitors and method of use
CN108794480A (zh) * 2017-04-28 2018-11-13 天津药物研究院有限公司 吡咯并嘧啶类化合物、其制备方法和用途
ES2910071T3 (es) 2018-03-08 2022-05-11 Incyte Corp Compuestos de aminopirazina diol como inhibidores de PI3K-Y
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
MX2020013896A (es) 2018-07-06 2021-03-09 Pfizer Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.
AU2019375412A1 (en) * 2018-11-05 2021-06-03 Avista Pharma Solutions, Inc. Chemical compounds
DK3915989T3 (da) * 2019-01-30 2023-09-18 Felicamed Biotechnology Co Ltd Jak inhibitor and preparation method therefor
US20220144846A1 (en) 2019-02-15 2022-05-12 Pfizer Inc. Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
WO2020182159A1 (zh) 2019-03-14 2020-09-17 上海华汇拓医药科技有限公司 Jak激酶抑制剂及其制备方法和在医药领域的应用
US20220259209A1 (en) * 2019-06-27 2022-08-18 Glenmark Life Sciences Limited Process for the preparation of abrocitinib
AU2020347561A1 (en) * 2019-09-11 2022-04-14 Pfizer Inc. Treatment of hidradenitis with JAK inhibitors
CA3177852A1 (en) 2020-04-04 2021-10-07 Pfizer Inc. Methods of treating coronavirus disease 2019
CN113637018A (zh) 2020-04-27 2021-11-12 苏州晶云药物科技股份有限公司 磺酰胺类化合物的晶型及其制备方法
BR112022021525A2 (pt) * 2020-05-28 2022-12-13 Pfizer Derivados de pirrolo [2,3-d] pirimidina
CN116917285A (zh) * 2020-09-11 2023-10-20 高德美控股有限公司 新型jak抑制剂化合物、其合成方法及其用途
JP2024505910A (ja) 2021-02-02 2024-02-08 ファイザー・インク 慢性手湿疹の処置のための投与レジメン
WO2023014049A1 (ko) * 2021-08-02 2023-02-09 한국화학연구원 신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
WO1994013676A1 (en) 1992-12-17 1994-06-23 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
JPH06329675A (ja) 1993-05-20 1994-11-29 Teijin Ltd ４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体
JPH06329674A (ja) 1993-05-20 1994-11-29 Teijin Ltd ４―置換シクロヘキシルアミノ―ピロロ［２，３―ｄ］ピリミジン
JPH08134068A (ja) 1994-11-02 1996-05-28 Teijin Ltd ４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体
US6051578A (en) 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
ID26698A (id) * 1998-06-19 2001-02-01 Pfizer Prod Inc SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
EP1175421A1 (en) 1999-04-30 2002-01-30 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
DK1235830T3 (da) 1999-12-10 2004-03-29 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer
AU3540101A (en) 2000-01-07 2001-07-16 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
EE200200711A (et) 2000-06-26 2004-06-15 Pfizer Products Inc. Pürrolo[2,3-d]pürimidiinühendid kui immunosupressiivsed vahendid
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
DE60234118D1 (de) 2001-11-30 2009-12-03 Osi Pharm Inc Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004032834A2 (en) 2002-10-04 2004-04-22 Merck & Co., Inc. Thrombin inhibitors
KR100742012B1 (ko) 2002-11-21 2007-07-23 화이자 프로덕츠 인코포레이티드 3-아미노-피페리딘 유도체 및 그의 제조 방법
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP1913000B1 (en) * 2005-07-29 2012-01-11 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
BRPI0709699A2 (pt) 2006-03-29 2011-07-26 Foldrx Pharmaceuticals Inc inibiÇço da toxidez da alfa-sinucleina
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
WO2008089310A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
JP2011503103A (ja) 2007-11-07 2011-01-27 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド タンパク質輸送の調節方法
JP2011503046A (ja) 2007-11-08 2011-01-27 ファイザー・インク シクロブチルカルボン酸誘導体
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
JP4884570B2 (ja) 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
EA201100368A1 (ru) 2008-09-18 2011-12-30 Пфайзер Лимитед Амидные соединения, полезные в терапии
IN2012DN02577A (el) * 2009-10-15 2015-08-28 Pfizer
TW201802091A (zh) 2009-12-01 2018-01-16 艾伯維有限公司 新穎三環化合物
JP5739446B2 (ja) * 2009-12-18 2015-06-24 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
CN102712640A (zh) 2010-01-12 2012-10-03 弗·哈夫曼-拉罗切有限公司 三环杂环化合物、其组合物和应用方法
WO2011104652A2 (en) 2010-02-24 2011-09-01 Pfizer Inc. Veterinary compositions
ES2704862T3 (es) 2010-07-16 2019-03-20 Agios Pharmaceuticals Inc Composiciones terapéuticamente activas y su método de uso
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
MX2013006251A (es) 2010-12-03 2013-10-01 Epizyme Inc Compuestos de purina y 7 - deazapurina substituidos como moduladores de enzimas epigeneticas.
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
EP2718283A4 (en) 2011-06-07 2014-10-29 Sumitomo Dainippon Pharma Co Ltd INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
JP2013010719A (ja) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
PL2796460T3 (pl) * 2011-12-21 2018-12-31 Jiangsu Hengrui Medicine Co. Ltd. Sześcioczłonowa pirolowa heteroarylowa pochodna pierścieniowa, sposób jej otrzymywania i zastosowania medyczne
WO2014011911A2 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP6022063B2 (ja) 2012-07-20 2016-11-09 ゾエティス・エルエルシー ヤヌスキナーゼ（ｊａｋ）阻害剤の投与計画
JP2014133739A (ja) 2012-12-12 2014-07-24 Dainippon Sumitomo Pharma Co Ltd インダゾール誘導体またはピロロピリジン誘導体からなる医薬
EP2958921B1 (en) * 2013-02-22 2017-09-20 Pfizer Inc Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus kinases (jak)
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase

Also Published As

Publication number Publication date
HUE041778T2 (hu) 2019-05-28
RS58245B1 (sr) 2019-03-29
CN105008362B (zh) 2017-06-06
MD4735B1 (ro) 2020-12-31
CL2015002303A1 (es) 2015-12-18
JP2016509049A (ja) 2016-03-24
JP2017165762A (ja) 2017-09-21
MY177476A (en) 2020-09-16
MX2015010928A (es) 2015-10-29
KR20150109434A (ko) 2015-10-01
ES2713052T3 (es) 2019-05-17
GEP201606600B (en) 2017-01-10
BR112015019634A2 (pt) 2019-12-17
AU2014220357B2 (en) 2017-04-27
HUS2200003I1 (hu) 2022-02-28
PH12015501779A1 (en) 2015-12-02
HRP20171599T1 (hr) 2017-12-01
LT2958921T (lt) 2017-11-27
PL2958921T3 (pl) 2018-01-31
KR101787858B1 (ko) 2017-10-18
UY35337A (es) 2014-09-30
NL301155I1 (el) 2021-12-22
ME03301B (me) 2019-07-20
TWI507408B (zh) 2015-11-11
SI3290421T1 (sl) 2019-03-29
PH12015501779B1 (en) 2015-12-02
US9545405B2 (en) 2017-01-17
CU24275B1 (es) 2017-10-05
RS56503B1 (sr) 2018-02-28
ZA201505454B (en) 2016-07-27
NZ710411A (en) 2017-11-24
ME02904B (me) 2018-04-20
PT3290421T (pt) 2019-03-01
UA111804C2 (uk) 2016-06-10
HRP20171599T2 (hr) 2018-11-16
NL301155I2 (nl) 2022-02-23
PT2958921T (pt) 2017-11-20
JP6145179B2 (ja) 2017-06-07
DK2958921T3 (da) 2017-11-06
EP3290421A1 (en) 2018-03-07
TW201443055A (zh) 2014-11-16
BR112015019634B1 (pt) 2022-09-20
NO3052752T3 (el) 2018-06-16
CN107089985B (zh) 2019-06-07
EP2958921B1 (en) 2017-09-20
MD4735C1 (ro) 2021-07-31
DK3290421T3 (en) 2019-03-18
DOP2015000206A (es) 2016-02-15
WO2014128591A1 (en) 2014-08-28
HUE037192T2 (hu) 2018-08-28
CR20150395A (es) 2015-09-23
CN107089985A (zh) 2017-08-25
CA2900703C (en) 2017-11-28
TN2015000355A1 (fr) 2017-01-03
IL240132B (en) 2020-09-30
US20150246048A1 (en) 2015-09-03
TR201902525T4 (tr) 2019-03-21
AP2015008664A0 (en) 2015-08-31
US20150225408A1 (en) 2015-08-13
EP2958921A1 (en) 2015-12-30
ES2647525T3 (es) 2017-12-22
HK1213881A1 (zh) 2016-07-15
CU20150078A7 (es) 2016-01-29
SI2958921T1 (sl) 2017-12-29
EA201591255A1 (ru) 2016-03-31
US9035074B2 (en) 2015-05-19
HRP20190152T1 (hr) 2019-03-22
EA027879B1 (ru) 2017-09-29
MD20150073A2 (ro) 2016-01-31
FR22C1006I2 (fr) 2023-01-27
FR22C1006I1 (fr) 2022-03-25
IL240132A0 (en) 2015-09-24
MA38347A1 (fr) 2017-10-31
US20140243312A1 (en) 2014-08-28
US9549929B2 (en) 2017-01-24
CA2900703A1 (en) 2014-08-28
AU2014220357A1 (en) 2015-08-06
LT3290421T (lt) 2019-02-25
PL3290421T3 (pl) 2019-05-31
EP3290421B1 (en) 2019-01-02
PE20151764A1 (es) 2015-12-03
AR094857A1 (es) 2015-09-02
LTPA2022502I1 (el) 2022-03-10
SG11201505816UA (en) 2015-09-29
CN105008362A (zh) 2015-10-28
CY1121468T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
CY1119502T1 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)
CY1123407T1 (el) Σταθερες υδατικες φαρμακοτεχνικες μορφες της αδαλιμουμαμπης
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
CY1122695T1 (el) Αλας toy omecamtiv mecarbil και διαδικασια για την παρασκευη αλατος
NI201500119A (es) Compuestos de heteroarilo y sus usos
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
EA201591420A1 (ru) Гетероарильные соединения и их применение
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
MX2017008520A (es) Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
CY1119042T1 (el) Υποκατεστημενες ξανθινες και μεθοδοι χρησης αυτων
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
TR201904658T4 (tr) Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
PH12016501567A1 (en) 4`-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201890820A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
EA201792689A1 (ru) Производные 2-(пиразолопиридин-3-ил)пиримидина в качестве ингибиторов jak
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
CY1122423T1 (el) Παραγωγα πυριμιδινης χρησιμα ως εκλεκτικοι αναστολεις jak3 kai/ή jak1
EA201591456A1 (ru) Макроциклические и бициклические ингибиторы вируса гепатита с
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола